Most favored nation pricing may well deliver lower drug costs in the short term. But the real ledger, measured in research not pursued, diseases not prioritized, and markets left behind, will take years to fully calculate.
Ariel Katz
Advertisement
Ariel Katz is CEO and co-founder of H1, a healhtcare technology company.
Articles by Ariel Katz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Providence CMO Rex Hoffman, M.D., MBA, reflects on building a career in healthcare leadership
2
Capital Rx is now Judi Rx in a company rebrand
3
Trade group for transparent PBMs has changed its name
4
Animal research finds investigational drug disrupts MASH by targeting gut-liver axis
5